Health

The vaccine against the new coronavirus could be ready by the end of September, according to a scientist leading one of the UK's most advanced teams.

A new study published in The Lancet by the University of Hong Kong stated that the researchers analyzed the stability of the new coronavirus in different environments.

Gilead published the first clinical research results of Remdesivir in the treatment of new coronavirus pneumonia (COVID-19) in the New England Medicine magazine.

Researchers in Finland have developed a computer model that shows how viruses move and spread in the air, thus illustrating the importance of avoiding crowded areas.

Professor Jin Dongyan, a molecular virologist from the University of Hong Kong's Li Ka Shing Faculty of Medicine, shared the theme of "The Past and Present of Human Coronavirus" online today.

Chinese scientists recently published an article titled "Structure of Mpro from COVID-19 virus and discovery of its inhibitors" on Nature, taking the lead in successfully analyzing the high-resolution three-dimensional space of the main protease (Mpro), a key drug target of the new coronavirus, structure.

Stanford University scientists are actively exploring whether gene editing technology can be used to fight epidemics, but so far, they have only solved a small part of the mystery.

Recently, people with asymptomatic infection with the new coronavirus pneumonia have attracted widespread attention, and many people may even get nervous.

At present, masks that protect doctors and nurses from new coronavirus infections can only play a protective role, but researchers from the University of Florida are developing a protective coating, which includes a new mask material, which can be used in several Stop and kill the virus in seconds.

China-based CanSino Biologics announced on April 9 that its recombinant new coronavirus vaccine (adenoviral vector) is planning to conduct a phase II clinical trial in China in the near future based on preliminary safety data from the phase I clinical trial.